SCHEMBL6805311

SCHEMBL6805311

Oc1cc2c(cc1O)C(=Cc1ccc(OCc3ccccc3)cc1)C1(Cc3ccccc3C1)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.45
PTPN1 P18031 3/20 0.45
HPGD P15428 3/20 0.45
POLB P06746 1/20 0.45
MAOA P21397 1/20 0.45
PPARG P37231 1/20 0.43
CYP1A2 P05177 2/20 0.43
LMNA P02545 1/20 0.43
PTGS1 P23219 1/20 0.43
SLC6A2 P23975 1/20 0.43
CYP2C19 P33261 1/20 0.43
PTGS2 P35354 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HIF1A Q16665 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
SLC5A1 P13866 1/20 0.42
SLC5A2 P31639 1/20 0.42
MMP3 P08254 1/20 0.42
MMP13 P45452 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799865 0.86 MAOB (0.47) MAOBPTPN1HPGDPOLBMAOA
SCHEMBL6800210 0.86 MAOB (0.47) MAOBPTPN1HPGDPOLBMAOA
SCHEMBL6806457 0.86 MAOB (0.47) MAOBPTPN1HPGDPOLBMAOA
SCHEMBL6800828 0.76 PPARG (0.38) MAOBPTPN1HPGDPOLBMAOA
SCHEMBL6795871 0.76 PPARG (0.38) MAOBPTPN1HPGDPOLBMAOA
SCHEMBL6800705 0.75 MAOB (0.39) MAOBPTPN1HPGDPOLBMAOA
SCHEMBL6800000 0.75 MAOB (0.39) MAOBPTPN1HPGDPOLBMAOA
SCHEMBL6797115 0.68 ALDH1A1 (0.42) HPGDPOLBPPARGCYP1A2CYP2C19
SCHEMBL6800031 0.68 MAOB (0.48) MAOBMAOA
SCHEMBL6800928 0.66 CES2 (0.53) MAOBHPGDMAOALMNAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082642-A1 Novel estrogen receptor ligands and method III MERCK & CO., INC. 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082642-A1 Novel estrogen receptor ligands and method III ESRRA, ESRRB, FSHR MAOB 1020/4885PTPN1 3641/4885HPGD 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.